Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Status:
Not yet recruiting
Trial end date:
2033-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk
neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard
induction therapy. The initial chemotherapy will include 5 cycles of multi-agent
chemotherapy. Naxitamab will be added to all 5 Induction cycles. Subjects with an ALK
mutation or amplification will have ceritinib added to their treatment regimen as soon as
results are available. We hypothesize that the addition of anti-GD2 therapy to induction
chemotherapy will result in improved end of induction responses and improved survival.